Physicians' opinions following pharmacogenetic testing for psychotropic medication

Psychiatry Research

Volumn 229, Issue 3, 2015, Pages 913-918

  Walden, Lucas M ^a   Brandl, Eva J ^a,b   Changasi, Amtul ^a,c   Sturgess, Jessica E ^a,d   Soibel, Alexander ^a   Notario, Janna Fe D ^a   Cheema, Sheraz ^a   Braganza, Nicole ^a   Marshe, Victoria S ^a,e   Freeman, Natalie ^a   Tiwari, Arun K ^a   Kennedy, James L ^a,c   Müller, Daniel J ^a,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF TORONTO   (Canada)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Clinical; Personalized medicine; Pharmacogenetics; Psychiatry medication; Survey

Indexed keywords

PSYCHOTROPIC AGENT;

ADULT; ARTICLE; CYP2C19 GENE; CYP2D6 GENE; FEMALE; GENE; GENETIC SCREENING; HUMAN; MALE; PHARMACOGENETICS; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; SEX DIFFERENCE; WORK EXPERIENCE; CANADA; GENERAL PRACTITIONER; HEALTH PERSONNEL ATTITUDE; MIDDLE AGED; PROCEDURES; PSYCHIATRY; QUESTIONNAIRE; TRENDS; YOUNG ADULT;

ADULT; ATTITUDE OF HEALTH PERSONNEL; CANADA; FEMALE; GENERAL PRACTITIONERS; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; PSYCHIATRY; PSYCHOTROPIC DRUGS; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84941260936     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2015.07.032     Document Type: Article

References (23)

1. Baker G.R., Norton P.G., Flintoft V., Blais R., Brown A., Cox J., Etchells E., Ghali W.A., Hebert P., Majumdar S.R., O'Beirne M., Palacios-Derflingher L., Reid R.J., Sheps S., Tamblyn R. The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada. Can. Med. Assoc. J. (CMAJ) 2004, 170:1678-1686.
2. Chou W.H., Yan F.X., de Leon J., Barnhill J., Rogers T., Cronin M., Pho M., Xiao V., Ryder T.B., Liu W.W., Teiling C., Wedlund P.J. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J. Clin. Psychopharmacol. 2000, 20:246-251.
3. CogentResearch, 2011. Americans Skeptical of Physicians' Knowledge of Genomics.
4. Daly A.K. Is there a need to teach pharmacogenetics?. Clin. Pharmacol. Ther. 2014, 95:245-247.
5. DeDiemar, S., 2014. Mental Wellness Milestone: 100,000 patients tested with GeneSight to support medication selection. Personalized Medicine Company Assurex Health Marks Significant Growth. Sets Goal of Testing One Million Patients by 2018.
6. de Denus S., Letarte N., Hurlimann T., Lambert J.P., Lavoie A., Robb L., Sheehan N.L., Turgeon J., Vadnais B. An evaluation of pharmacists' expectations towards pharmacogenomics. Pharmacogenomics 2013, 14:165-175.
7. Drozda K., Muller D.J., Bishop J.R. Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options. Pharmacotherapy 2014, 34:166-184.
8. Gibbs, C., Fisher, P., Hernandez, J., Mrazek, D., O'Kane, D., Snyder, K., 2005. Cytochrome P450 Enzyme Genotyping: Optimizing Patient Care Through Pharmacogenetics. In: Services, M.R. (Ed.), pp. 1-10.
9. Godman B., Finlayson A.E., Cheema P.K., Zebedin-Brandl E., Gutierrez-Ibarluzea I., Jones J., Malmstrom R.E., Asola E., Baumgartel C., Bennie M., Bishop I., Bucsics A., Campbell S., Diogene E., Ferrario A., Furst J., Garuoliene K., Gomes M., Harris K., Haycox A., Herholz H., Hviding K., Jan S., Kalaba M., Kvalheim C., Laius O., Loov S.A., Malinowska K., Martin A., McCullagh L., Nilsson F., Paterson K., Schwabe U., Selke G., Sermet C., Simoens S., Tomek D., Vlahovic-Palcevski V., Voncina L., Wladysiuk M., van Woerkom M., Wong-Rieger D., Zara C., Ali R., Gustafsson L.L. Personalizing health care: feasibility and future implications. BMC Med. 2013, 11:179.
10. Haga S.B., Burke W., Ginsburg G.S., Mills R., Agans R. Primary care physicians' knowledge of and experience with pharmacogenetic testing. Clin. Genet. 2012, 82:388-394.
11. Hicks J.K., Swen J.J., Thorn C.F., Sangkuhl K., Kharasch E.D., Ellingrod V.L., Skaar T.C., Muller D.J., Gaedigk A., Stingl J.C. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin. Pharmacol. Ther. 2013, 93:402-408.
12. Hoop J.G., Roberts L.W., Green Hammond K.A., Cox N.J. Psychiatrists' attitudes regarding genetic testing and patient safeguards: a preliminary study. Genet. Test. 2008, 12:245-252.
13. Kirchheiner J., Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim. Biophys. Acta 2007, 1770:489-494.
14. Kirchheiner J., Nickchen K., Bauer M., Wong M.L., Licinio J., Roots I., Brockmoller J. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 2004, 9:442-473.
15. Klitzman R., Abbate K.J., Chung W.K., Marder K., Ottman R., Taber K.J., Leu C.-S., Appelbaum P.S. Psychiatrists' views of the genetic bases of mental disorders and behavioral traits and their use of genetic tests. J. Nerv. Ment. Dis. 2014, 202:530-538.
16. Lanktree M.B., Zai G., Vanderbeek L.E., Giuffra D.E., Smithson D.S., Kipp L.B., Dalseg T.R., Speechley M., Kennedy J.L. Positive erception of pharmacogenetic testing for psychotropic medications. Hum. Psychopharmacol. 2014, 29:287-291.
17. Müller D.J., Kekin I., Kao A.C., Brandl E.J. Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. Int. Rev. Psychiatry 2013, 25:554-571.
18. Sallee F.R., DeVane C.L., Ferrell R.E. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J. Child Adolesc. Psychopharmacol. 2000, 10:27-34.
19. Selkirk C.G., Weissman S.M., Anderson A., Hulick P.J. Physicians' preparedness for integration of genomic and pharmacogenetic testing into practice within a major healthcare system. Genet. Test. Mol. Biomark. 2013, 17:219-225.
20. Singh A.B., Bousman C.A., Ng C., Berk M. Antidepressant pharmacogenetics. Curr. Opin. Psychiatry 2014, 27:43-51.
21. Stanek E.J., Sanders C.L., Taber K.A., Khalid M., Patel A., Verbrugge R.R., Agatep B.C., Aubert R.E., Epstein R.S., Frueh F.W. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin. Pharmacol. Ther. 2012, 91:450-458.
22. Thompson C., Hippman C., Hamilton S.P. Psychiatrist attitudes towards pharmacogenetic testing, direct-to-consumer genetic testing, and integrating genetic counseling into psychiatric patient care. Psychiatry Res. 2014.
23. Winner J., Allen J.D., Altar C.A., Spahic-Mihajlovic A. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl. Psychiatry 2013, 3:e242.